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Abstract
Background: The efficacy and/or tolerability of pazopanib in patients with metastatic renal cell carcinoma (mRCC)
have been found to differ in Western and Asian populations. This retrospective multicenter study analyzed the
results of first-line pazopanib treatment in 93 consecutive patients with mRCC who were treated at the medical
oncology departments of three tertiary cancer centers in Seoul, Korea.
Methods: The decision to administer pazopanib as first-line therapy was at the discretion of the treating physician
in all patients with mRCC. Patients enrolled in clinical trials were excluded to ensure that the results would reflect
real-world outcomes representative of daily clinical settings. All patients received 800 mg/day pazopanib. Outcomes
included response rate, progression-free survival (PFS), overall survival (OS), and safety.
Results: The 93 patients included72 (77 %) male and 21 (23 %) female individuals, of median age 65 years (range,
19–84 years). The median number of metastatic sites per patient was two (range, 1–5), with the lungs being the
most frequently involved site. Most patients had favorable (n = 46) or intermediate (n = 36) risk as determined by
Memorial Sloan Kettering Cancer Center criteria. Pazopanib was generally welltolerated: the major hematologic
adverse effect was grade 1/2 anemia (14 %); and the most frequently observed non-hematologic toxicity was grade
1/2 mucositis (22 %), followed by hair discoloration and hypertension. Of the 93 patients, three (3 %) showed
complete response, 52 (56 %) showed partial response, and 21 (23 %) showed stable disease, making the objective
response rate 59 % and the disease control rate 82 %. At a median follow-up of 21 months, the estimated median
PFS and OS were 12.2 months (95 % confidence interval, 7.1–17.4 months) and 21.9 months (95 % confidence
interval, 12.9–30.9 months), respectively.
Conclusions: In this retrospective study, first-line therapy with pazopanib demonstrated clinically relevant efficacy
and tolerability in unselected real-world Korean patients with mRCC. OS and PFS of these Korean patients were
similar to those reported in phase III trials.
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Background
Renal cell carcinoma (RCC) is the most common type of
kidney cancer [1], with clear cell carcinoma being the
most common subtype. Because approximately 30 % of
patients present with primary metastatic disease and
one-third of patients have recurrent metastatic disease
after nephrectomy with curative intent [2], over 50 % of
all patients with RCC require systemic therapy during
the course of their disease. RCC has been found refrac-
tory to conventional systemic chemotherapeutic agents
and radiotherapy. Clear cell RCC represents a unique
clinical setting for the application of antiangiogenic ther-
apy, in that targeting of angiogenesis through pathways
involving vascular endothelial growth factor receptor
(VEGFR) and mammalian target of rapamycin has pro-
duced robust clinical effects and revolutionized the
treatment of metastatic RCC [3]. Multi-targeted tyrosine
kinase inhibitors (TKIs) against VEGFR, including suni-
tinib [4], sorafenib [5], and pazopanib [6], have improved
progression-free survival (PFS) and/or overall survival
(OS) when compared with interferon and/or supportive
care in patients with metastatic RCC.
Current guidelines recommend the use of sunitinib,
pazopanib, or bevacizumab plus interferon as first-line
treatment for favorable- or intermediate-risk patients
with metastatic, clear cell RCC [7]. Because of their oral
route of administration and more favorable toxicity pro-
files, sunitinib and pazopanib are the most widely ad-
ministered TKIs in this setting. The choice of a first-line
regimen is important, because not all patients are eli-
gible for salvage therapy, providing an obvious rationale
for administering the most effective initial treatment.
For example, in the large phase IIICOMPARZ (COM-
Paring the efficacy, safety and tole Rability of paZopanib
versus sunitinib) trial [8], 1,110 patients with metastatic
RCC were randomly assigned to receive either sunitinib
or pazopanib. Baseline patient and disease characteristics
were well balanced between the two arms. Based on in-
dependent review by blinded radiologists, median PFS
was 8.4 months in the pazopanib group versus
9.5 months in the sunitinib group, with the hazard ratio
(HR) of 1.05 (95 % confidence interval [CI] 0.90–1.22)
being within the acceptable boundaries of non-
inferiority. Although pazopanib and sunitinib showed
similar efficacy, safety and quality-of-life (QOL) profiles
favored pazopanib. These findings were confirmed in the
subsequent randomized, double-blind, crossover PISCES
(PazopanIb versus Sunitinib patient preference Study)
study, which compared QOL and patient preference in
patients treated with pazopanib or sunitinib [9].
Based on these results, pazopanib has become one of
the most frequently used VEGFR TKIs for metastatic
RCC in Korea. However, the choice of a first-line TKI
for an individual patient can be a clinical dilemma.
Factors that must be considered include the experiences
of the treating oncologists, the activities of the TKIs, and
the potential toxicities of these agents, especially for pa-
tients with symptoms or decreased performance status.
Moreover, the efficacy and/or tolerability of pazopanib-
has been found to differ in Western and Asian popula-
tions. For example, subset analysis of the COMPARZ
trial [10] found that, in Asian patients, median PFS was
longer with sunitinib than with pazopanib (11.1 versus
8.4 months, HR 1.07, 95 % CI 0.81–1.42), although the
difference was not statistically significant. In addition,
Asian and non-Asian RCC patients experienced different
adverse events: hematologic toxicities, hypertension, and
hand-foot-syndrome were more frequently observed in
Asian patients, whereas fatigue and gastrointestinal
symptoms were more frequent in non-Asians, regardless
of treatment arm. Patients in phase III clinical studies,
including COMPARZ, were selected on the basis of a
fairly preserved performance status and normal organ
function. However, RCC is a highly aggressive disease,
which often shows rapid progression and clinical decline;
therefore, the clinical trial population may not be repre-
sentative of all patients seen in real-world daily oncology
practice. Based on these considerations, this multi-
center retrospective studywas designed to evaluate the
efficacy and safety of first-line pazopanib in Korean pa-
tients with RCC.
Methods
The medical records of 93 consecutive adults with histo-
logically proven mRCC and predominant clear cell hist-
ology who were treated with pazopanib as first-line TKI
therapy in 2012 were retrospectively reviewed. The deci-
sion to treat with pazopanib was solely at the discretion
of the treating oncologist. Patients enrolled in clinical
trials were excluded to ensure that the study population
reflected daily clinical practice in our institutions. Pa-
tients were also excluded if they had: (1) received prior
chemotherapy or anti-angiogenic therapy for advanced
or metastatic disease, (2) 100% non-clear cell carcin-
oma,(3) another malignancy within 5 years, and (4) in-
appropriate laboratory findings or severe comorbid
illness during treatment with the standard dose of pazo-
panib (800 mg/day). This study was approved by the In-
stitutional Review Boards of Samsung Medical Center,
Asan Medical Center, and Seoul National University
Hospital. Written informed consent was provided by all
patients prior to starting pazopanib treatment, according
to institutional standards.
All patients were treated with 800 mg/day pazopanib,
administered orally without interruption. Supportive
care, including the administration of blood products and
analgesics, was provided if judged appropriate by the
treating physician. Before treatment with pazopanib,
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patients had a complete history taken and underwent
complete blood counts and serum chemistries, chest x-
rays, and computed tomography scans of all involved
sites. Patients were assessed every 4 weeks because pazo-
panib therapy was repeated at this interval. Therapy was
continued until objective disease progression per Re-
sponse Criteria in Solid Tumors [11], unacceptable tox-
icity or deterioration of hepatic function, or patient
refusal. Baseline characteristics and outcome data were
collected using a uniform case report form. Clinical and
laboratory parameters collected at the time of starting
pazopanib treatment included, but were not restricted
to, those described inthe Memorial Sloan Kettering Can-
cer Center (MSKCC) [2] and Heng [12] prognostic cri-
teria: age, sex, Eastern Cooperative Oncology Group
(ECOG) performance status, the presence of other histo-
logic types than clear cell carcinoma, previous nephrec-
tomy, previous cytokine therapy, neutrophil count,
platelet count, hemoglobin, serum lactate dehydrogen-
ase, corrected serum calcium, time between diagnosis
and TKI therapy, and sites of metastases. Responses
were evaluated every 8 weeks by chest and abdominopel-
vic computed tomography or by the same tests that were
used to stage initial tumors. Adverse events were graded
according to the National Cancer Institute criteria
(CTCAE v4). Causes of death and discontinuation of
therapy were evaluated by a structured review of medical
records.
The primary endpoint was PFS, defined as the time
between pazopanib initiation and the date of docu-
mented disease progression or death, whichever oc-
curred first. Secondary endpoints included OS, response
rate, and toxicity profile. OS was defined as the time
from the first day of pazopanib administration to death
from any cause. PFS and OS were calculated using the
Kaplan–Meier method. The impact of baseline parame-
ters on PFS and OS was assessed using a Cox propor-
tional hazards model. Laboratory parameters and age
were recorded as continuous variables and were evalu-
ated as both continuous and categorical variables. The
potential presence of interaction effects between baseline
parameters was tested by defining product terms for the
respective factors in a regression model. All P values
were two-sided, with P < 0.05 indicating statistical sig-
nificance. All statistical analyses were performed using
the SPSS package (version 16.0) and R for Windows
v2.11.1 software (R Core Team, Vienna, Austria; http://
www.Rproject.org).
Results
Medical records were collected from 93 consecutive pa-
tients who were treated with first-line pazopanib at three
tertiary Korean cancer centers between January and De-
cember 2012. Patient characteristics are given in Table 1.
Table 1 Baseline characteristics
No. of patients Percent
Age, years












Obstructive lung disease 11
Renal insufficiency 3
Histology
Clear cell carcinoma (100 %) 87 93
Mixed 6 7
Time from diagnosis to treatment, months
Median (range) 14 (0–83)
Prior therapy
Nephrectomy 74 80
Cytokine immunotherapy 9 10
Radiotherapy 6 7
Laboratory findings (mean, SD)
Hemoglobin, g/dL 12.6 (2.0)
Corrected calcium, mg/dL 9.3 (0.7)
Lactate dehydrogenase, U/L 372 (243)
Number of metastatic site(s)
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Of the 93 patients, 72 (77 %) were male individuals and
21 (23 %) were female individuals. Nine (10 %) patients
had previously been treated with cytokine therapy, the
majority with high-dose interleukin-2. Eighty-two (88 %)
patients had favorable or intermediate MSKCC risk
scores, whereas 11 (12 %) had an ECOG performance
status of 2 or higher. Approximately 60 % of the patients
had two or more metastatic disease sites, mostly involv-
ing the lungs and lymph nodes. At the time of data col-
lection, corresponding to a median follow-up of
21 months, 82 patients (88 %) had discontinued pazopa-
nib treatment and 40 (43 %) had died.
The 93 patients received a total of 1,086 4-week cycles
of pazopanib (median 12, range 1–34). In 32 cycles
(0.03 %), involving 12 (13 %) of the 93 patients, doses
were reduced by 25 %. The reasons for dose reduction
were available for 11 patients, the most common being
non-hematologic toxicities, including fatigue (4/11,
36 %), gastrointestinal discomfort (3/11, 27 %), and
hypertension (2/11, 18 %). In addition, two (18 %) of
these 11 patients required dose reductions for hema-
tologic toxicities, both being grade 3 thrombocytopenia.
The most common reason for therapy discontinuation
was disease progression, Overall, first-line pazopanib
was generally well tolerated, with hypertension, anemia,
and oral mucositis being the most commonly observed
toxicities (Table 2). Twelve (13 %) patients experienced
transient and reversible elevation of liver function tests
(LFTs); of these, one patient had early liver cirrhosis
owing to hepatitis B virus infection and three were
heavy consumers of alcohol, whereas the other eight
had no underlying hepatic diseases. All 12 patients
received ursodeoxycholic acid to normalize LFTs, but
none requirement pazopanib dose modification or
delay. Abnormal LFTs were all normalized within
3 months. Two patients died of causes for which we
could not completely rule out a relationship to pazo-
panib. One patient died of a pulmonary thrombo-
embolism during the middle of the second cycle of
pazopanib treatment, with no clinical evidence of pro-
gression. The second patient, who had multiple lung
and lymph node metastases, died of interstitial pneu-
monitis after 12 months of clinical response to pazo-
panib. Although the size of involved lymph nodes
remained unchanged, the possibility of disease pro-
gression could not be completely excluded.
Of the 93 patients, two could not be evaluated for re-
sponse to pazopanib because of the absence of measur-
able lesions or early discontinuation of therapy. Three
(3 %) patients showed a complete response (CR) and 52
(56 %) had a partial response, making the objective re-
sponse rate 59 % (95 % CI 45–65 %). In addition, 21
(23 %) patients had stable disease, making the disease
control rate 82 %. Patients with poor MSKCC risk scores
were significantly less likely to respond to pazopanibthan
patients with favorable or intermediate risk scores (P =
0.03). Response rate was not significantly influenced by
age, sex, number and site of metastases, or baseline la-
boratory parameters.
The median OS forthe 93 patients analyzed in the
study was21.9 months (95 % CI 12.9–30.9 months, Fig. 1)
and the median PFS was 12.2 months (95 % CI 7.1–
17.4 months, Fig. 2). Median PFS was significantly
shorter for patients with poor risk than for patients with
favorable or intermediate MSKCC riskscores (2.4 months
[95 % CI 2.0–2.8 months] vs. 12.5 months [95 % CI 8.3–
16.7 months], P < 0.0001). Similarly, median OS was
shorter for patientswith poor risk than for patient with
favorable or intermediate MSKCC risk scores
(7.2 months [95 % CI 1.5–12.9 months] vs. 26.5 months
[95 % CI 18.9–34.1 months], P < 0.001; Fig. 3). This
model suggested that mRCC patients with poor MSKCC
risk scores had a 4-fold higher risk of death than
Table 2 Maximum grade toxicity recorded per patient (n = 93)
Grade 1–2 Grade 3–4
N % N %
Anemia 19 20 1 1
Neutropenia 2 2 0
Thrombocytopenia 12 13 0
Nausea 3 3 0
Vomiting 2 2 0
Anorexia 6 7 0
Stomatitis 20 22 2 2
Diarrhea 15 16 3 3
Fatigue 9 10 1 1
Skin 11 12 0
Hepatic 12 13 0
Hypertension 22 24 0 Fig. 1 Kaplan–Meier analysis of overall survival of all patients
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patients with favorable or intermediate risk scores. We
also tested whether OS was altered by interactions with
poor MSKCC risk scores and other clinical characteris-
tics by entering the first-level interaction term between
these variables into separate multivariate models; how-
ever, the results were not significant.
For exploratory purposes, we compared OS according
to the clinical response to pazopanib. OS was longer in
responders (26.7 months) than in non-responders
(18.6 months), although this difference was statistically
insignificant (P = 0.106).In contrast, OS was significantly
longer in patients who did than did not achieve clinical
response or stable disease (26.5 months vs. 14.8 months,
P = 0.007). After the failure of pazopanib treatment,
37 % of the patients received second-line therapy, mostly
with everolimus (n = 30) or another VEGFR TKI (n = 4).
Discussion
This retrospective study on a limited number of Korean
RCC patients showed that first-line therapy with pazopa-
nib was both well tolerated and effective, regardless of
performance status or the number of metastases. Pazo-
panib achieved an objective response and stable disease
in 59 and 23 % of patients, respectively. The estimated
median PFS and OS were 12.2 months (95 % CI, 7.1–
17.4 months) and 21.9 months (95 % CI, 12.9–
30.9 months), respectively. These results compared fa-
vorably with the outcomes of large phase III trials [6, 8].
Although this study was retrospective in nature, its re-
sults indicate that Korean patients with metastatic RCC
may derive clinically relevant benefits from pazopanib.
Most adverse events were transient and self-limiting,
and there were few severe non-hematologic toxicities,
with grade 3 or 4 stomatitis or diarrhea occurring in
only 2–3 % of patients.
VEGFR TKIs have been the mainstay of treatment of
patients with clear cell mRCC. Because the main goal of
treatment remains palliation, the choice of TKI is based
not only on efficacy, but on the consideration of other
parameters, include patient preference, relief of symp-
toms, and/or QOL. The phase III COMPARZ trial, a dir-
ect head-to-head comparison between sunitinib and
pazopanib indicated that both TKIs are effective and
feasible for the first-line treatment of patients with
mRCC [8]. Although these two TKIs had similar efficacy,
safety and QOL data favored pazopanib. Interestingly,
subgroup analysis of patients in the COMPARZ trial
showed marked geographic and/or ethnic differences in
toxicity profiles and efficacy. In Asian patients, the me-
dian PFS was longer with sunitinib (11.1 months) than
with pazopanib (8.4 months) [10], although the differ-
ence was not statistically significant (HR 1.07, 95 % CI
0.81–1.42). One possible explanation is that the inci-
dence of adverse events differs according to ethnicity.
The discontinuation rate owing to adverse events in the
COMPARZ trial was 20 % for sunitinib and 24 % for
pazopanib. Asian RCC patients experienced hematologic
toxicities, hypertension, hand-foot syndrome, liver dys-
function, and proteinuria more frequently than non-
Asian patients, whereas fatigue and gastrointestinal
symptoms were observed less frequently in Asian pa-
tients, regardless of the treatment arm.
In contrast to the COMPARZ subgroup results [10],
sunitinib is thought to be less well tolerated by Asian
than Western RCC patients, leading to the widespread
administration of reduced suboptimal doses of sunitinib
to Asian patients [13]. Because of the clear-cut relation-
ship between drug exposure and efficacy [14], maintain-
ing adequate TKI doses is essential to optimize
treatment outcomes in Asian RCC patients [15]. These
ethnicity-based differences may be owing to chance, to
Fig. 2 Kaplan–Meier analysis of progression-free survival of
all patients
Fig. 3 Kaplan–Meier analysis of overall survival according to MSKCC
risk scores. Overall survival was significantly greater in patients with
favorable or intermediate risk scores (solid line) or a poor risk score
(dotted line) (hazard ratio, 4.07; 95 % confidence interval,
1.84–9.01; P = 0.001)
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differences in tumor biology between Asian and Western
patients, or to a pharmacogenomic difference in drug
metabolism leading to differences in drug exposure.
It is difficult to determine whether pazopanib or suni-
tinib is more effective in Asian patients with mRCC,
even when including results from the analysis of Asian
subpopulations in a sunitinib expanded access program
[16]. Choice of a first-line TKI regimen for individual pa-
tients with mRCC requires careful considerations of
eachpatient’s disease status, symptoms, general condi-
tion, and preference. The results of the present study in-
dicate that pazopanib is a reasonable option for Korean
mRCC patients and that poor MSKCC risk score is a
significant predictor of reduced survival. Studies are un-
derway to identify possible molecular markers, as well as
specific genotypic variations in different ethnicities,
which may be linked to responsiveness or resistance to
VEGFR TKIs.
The strength of the current study includes its multi-
center nature and the enrollment of patients who were
treated with pazopanib as routine clinical practice to
avoid selection bias. The patients included in this study
were those treatedat academic tertiary cancer centers,
reflecting real-world experience with first-line pazopa-
nib. This population may differ from those in clinical tri-
als and may be more relevant to those seen by the
clinicians in daily practice. That is, the results of this
study may better reflect real-world outcomes that may
not necessarily be seen in randomized controlled trials
of selected patients.
This study also had several limitations, including its
retrospective nature, which may have introduced selec-
tion bias and issues regarding missing data. However, se-
lection bias can be minimized by evaluating a
consecutive series of patients, as in the current study.
Other limitations include the lack of central radiology
review, the use of various imaging modalities, and differ-
ent intervals between scans; however, these variations
better reflect the real-world clinical experience of oncol-
ogists who administer targeted therapy. Finally, the lack
of a comparative arm precludes our ability to determine
whether pazopanib is superior, or at least equivalent, to
other agents such as sunitinib.
Conclusions
The results obtained in the present study suggest that
pazopanib is active and safe in the first-line treatment of
Korean patients with mRCC. Better patient selection
may improve clinical outcomes of mRCC patients in a
first-line setting. Emerging clinical data and greater
knowledge of the disease may further guide the develop-
ment of individualized treatment regimens for patients
with mRCC.
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